| |
Tuesday, January 24, 2023 | 1:00pm ET This session will discuss key 2023 trends for healthcare and life sciences and how organizations should think about their data strategy and interoperability as they navigate the winds of change. Register now.
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| By Fraiser Kansteiner As many in the U.S. struggle with rising costs of living, large pharmaceutical companies have opted to ring in the New Year with price hikes. |
|
|
|
By Annalee Armstrong A third patient death potentially tied to Eisai and Biogen’s Alzheimer’s disease drug lecanemab has been reported in a phase 3 extension study, according to a report from Science. |
By Kevin Dunleavy Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2022, however, fewer drugs were approved than was typical in recent years. Is this the result of the FDA becoming gun-shy after its much-criticized sanction of Biogen's Alzheimer's disease treatment, Aduhelm, in 2021? Or was 2022 just a cyclical blip on the approval landscape? |
By Annalee Armstrong Fierce Biotech recounts the biggest biotech blunders and one refreshing reparation in the 2022 edition of Rotten Tomatoes. |
|
Wednesday, January 11, 2023 | 2:00pm ET Recent advances in natural language processing (NLP) caused an explosion of practical use cases that have now become viable. This webinar for healthcare & life sciences leaders surveys common NLP applications that are being widely deployed, including real world data extraction from pathology & radiology reports, patient risk adjustment & HCC coding, and more. Register now.
|
|
By Annalee Armstrong,Gabrielle Masson,Max Bayer Layoffs hit biotech fast and furious in 2022. The Fierce Biotech Layoff Tracker lists the reported events from January to December. |
By Fraiser Kansteiner Novartis is cutting 285 jobs across three New Jersey sites, according to a local Worker Adjustment and Retraining Notification Act notice. |
By Annalee Armstrong In one of the most lopsided biobucks deals this publication has ever seen, Merck & Co. is offering $175 million upfront to Kelun-Biotech for seven antibody-drug conjugates, plus an eye-popping $9.3 billion in potential milestones on the tail end. |
By Fraiser Kansteiner It’s been nearly a year since Novo Nordisk revealed a supply shortfall for its obesity blockbuster-to-be Wegovy. Now, it appears history is repeating for the company’s chief rival, Eli Lilly. |
By Andrea Park Right after a major win for Apple in its patent dispute with fellow wearable device maker AliveCor, the tech giant has hit a roadblock. |
By Ben Adams Roche’s biotech unit Genentech is making major moves in marketing for 2023 as it creates two new roles aimed at boosting engagement with patients and healthcare professionals. |
By Max Bayer Merck KGaA is continuing its recent run of dealmaking, handing over an IL-12-targeting cancer med to PDS Biotech in a deal worth more than $120 million. The med is being tested as part of a triple combo therapy that also includes PDS Biotech's lead immunotherapy asset. |
By Helen Floersh Dry eye disease isn’t just uncomfortable—it also puts patients at greater risk of corneal injury. Now, scientists may have identified a new approach to protecting them. |
By Nick Paul Taylor Eli Lilly and Merck & Co. have identified PeptiDream’s peptides as a way to deliver therapeutic payloads to targets, leading them both to lay down more than $1 billion in milestones to work with the biotech. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Thursday, February 2, 2023 | 11am ET/8am PT Regulators have made it abundantly clear - through recent guidance and inspection findings - that demonstrating sponsor oversight of an outsourced study is a critical requirement for TMF health and inspection-readiness. Join this webinar to discover how global biopharmaceutical company Chiesi and its CRO partners collaborate to ensure ongoing oversight compliance, in the face of increasing documentation requirements and trial complexity. Register now.
|
|
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| eBook Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
